Signatera Looks Deeper
On-Demand ESMO Presentations
FEATURED PRESENTATION AT ESMO
Personalized circulating tumor DNA assay for the detection of minimal residual disease in CRC patients undergoing resections of metastases.
Personalized circulating tumor DNA assay for the detection of minimal residual disease in CRC patients undergoing resections of metastases.
Fotios Loupakis, MD, PhD
Department of Oncology, Istituto Oncologico Veneto, Italy
POSTER PRESENTATION
-
From scientists, engineers and statisticians to lab associates, genetic counselors and medical educators, there are Naterans behind every test sample received, working to provide patients and providers insightful genetic information.
Abstract #: 520TiP
Pashtoon Kasi, MD, MSDivision of Hematology, Oncology and Bone Marrow Transplantation, University of Iowa, USA -
MRD detection and tracking tumor evolution using ctDNA in stage I-III colorectal cancer patients
Abstract #: 420P
Tenna V Henriksen, MSDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark -
Bespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients
Abstract #: 1491P
Emma Ococks, MSMRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, United Kingdom
Dive Deeper
ctDNA and MRD Testing | Colorectal Cancer Care Tools for Surveillance
Video
Seeing beyond the limit: Detect residual disease and assess treatment response
Whitepaper
A personalized, tumor informed approach to detect molecular residual disease with high sensitivity and specificity
Whitepaper